Ravi Salgia to Proteomics
This is a "connection" page, showing publications Ravi Salgia has written about Proteomics.
Connection Strength
0.449
-
Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev. 2007 May-Jun; 26(3):451-66.
Score: 0.265
-
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
Score: 0.105
-
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
Score: 0.041
-
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. J Proteomics. 2019 02 10; 192:233-245.
Score: 0.037